Background
Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are oral medications that promote glucose excretion in the urine for the
treatment of type 2 diabetes. Note that SGLT2i are not approved for use in the management of type 1 diabetes in Australia or
New Zealand, although they are sometimes used off-label in this setting.

Click below for the full update.

ADS_DKA_SGLT2i_Alert_update_2020

Please wait...

Subscribe to our Monthly eNews

Receive the latest diabetes news, education, resources and special offers!